23andMe picks up FDA clearance; Sun Pharma founder set to become India's richest man;

@FierceBiotech: EuroBiotech Report: Novartis makes Israel a priority, U.K. dreams up Alzheimer's R&D hub, Shire defends tax model. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: I love this Pronutria story. VC insiders, star scientist, homeostasis focus on oral biologics. It's what makes Boston/Cambridge special. Article | Follow @JohnCFierce

@DamianFierce: Cerecor is repurposing an old $LLY antidepressant for addiction. Release | Follow @DamianFierce

> 23andMe finally convinced the FDA to let it market its genetic test straight to consumers, as the agency cleared the Personal Genome Service as a screen for the rare Bloom syndrome. News

> Thanks to his company's pending merger with Ranbaxy, Sun Pharmaceutical founder Dilip Shanghvi is set to become the richest man in India. More

Medical Device News

@FierceMedDev: Integra LifeSciences lays off 49 in Massachusetts as part of facility consolidation drive. Article | Follow @FierceMedDev

@VarunSaxena2: UPDATED w/ $GE response GE recalls 10,000+ MRI systems after FDA deems them potentially deadly, citing poor training. Article | Follow @VarunSaxena2

@EmilyWFierce: Check out our weekly roundup of FierceLifeSciences news here! Newsletter | Follow @EmilyWFierce

> KKR-backed Panasonic Healthcare to buy Bayer diabetes device biz for as much as $2.3B. More

> 23andMe nabs FDA marketing clearance for direct-to-consumer genetic carrier test. Story

> New studies shed light on power morcellator devices in surgical procedures. Article

Pharma News

@FiercePharma: Sanofi names Paris-trained Olivier Brandicourt CEO. He will begin at Sanofi April 2. Report | Follow @FiercePharma

@CarlyHFierce: ICYMI earlier: Protein Sciences halts Connecticut expansion in response to governor's use of rival flu shot. FierceVaccines story | Follow @CarlyHFierce

> Valeant closing in on $160-per-share Salix deal: Reuters. More

> Ex-Merck analyst pleads guilty to insider trading. Item

> Sanofi makes it official--Brandicourt is its man. Report

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.